Last reviewed · How we verify
Suboxone Sublingual Film
At a glance
| Generic name | Suboxone Sublingual Film |
|---|---|
| Also known as | buprenorphine, naloxone, SUBOXONE, Buprenorphine and naloxone, buprenorphine HCl and naloxone HCl dihydrate |
| Sponsor | Indivior Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Bundled Intervention - Phase 2 (PHASE4)
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder (PHASE1)
- Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine (PHASE2, PHASE3)
- Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (PHASE4)
- Medication Maintenance Therapy in Community Pharmacy Settings (PHASE2, PHASE3)
- Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films (PHASE2)
- Virginia Opioid Overdose Treatment InitiatVE (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suboxone Sublingual Film CI brief — competitive landscape report
- Suboxone Sublingual Film updates RSS · CI watch RSS
- Indivior Inc. portfolio CI